Transcriptomics of Anterior Shoulder Instability: Differences in Gene Expression in the Blood of Patients With and Without Significant Glenoid Bone Loss— MHSRS 2023

Galvin J, Rooney p, Egan a, tokish j, Grassbaugh j, Masini b, free k, bastian m, gillette l, colburn z

Abstracted accepted for a poster session at the 2023 Military Health System Research Symposium

Currently, the measurement of serum or synovial biomarkers does not have a role in diagnosis or monitoring of injury severity in young patients with recurrent anterior shoulder instability. The purpose of this study was to compare gene expression differences in the blood and tissue of young patients with anterior shoulder instability with and without significant glenoid bone loss (GBL). Additionally, we sought to identify a blood transcriptomic biomarker for the reliable delineation of the severity of GBL.

There are significant gene expression differences in the blood of anterior shoulder instability patients with and without significant (≥10%) GBL.

The differential expression of 5 genes allowed development of an accurate predictive model and transcriptomic biomarker to predict the severity of GBL.

This novel blood transcriptomic data may assist in tracking GBL and injury progression in patients with recurrent anterior shoulder instability.